Role of the Sympathetic Nerve System for the Pathogenesis and Progression of Chronic Kidney Failure
Overview
- Phase
- Phase 4
- Intervention
- Rilmenidine
- Conditions
- Chronic Kidney Disease
- Sponsor
- University of Erlangen-Nürnberg Medical School
- Locations
- 1
- Primary Endpoint
- sympathetic activation for the development and progression of chronic renal failure
- Status
- Withdrawn
- Last Updated
- 11 years ago
Overview
Brief Summary
The primary purpose is to assess the role of sympathetic activation for the development and progression of chronic renal failure. Using microneurography sympathetic activity will be registered in various stages of kidney affection or failure and hypertension.
A sympatholytic agent will be compared with a non-sympatholytic drug to asses the effect sympathetic activation and on the progression of kidney disease.
The effects of a sympatholytic agent on cardiovascular reactivity to various stressors wil be examined.
Investigators
Eligibility Criteria
Inclusion Criteria
- •chronic renal failure stages I-IV
Exclusion Criteria
- •pregnancy and lactation
- •severe heart failure or ischemic heart disease
- •patients with NYHA III-IV
Arms & Interventions
Arm 1
Rilmenidine as a sympatholytic agent for three months
Intervention: Rilmenidine
Arm 2
Nitrendipine as a non-sympatholytic agent for three months
Intervention: Nitrendipine
Outcomes
Primary Outcomes
sympathetic activation for the development and progression of chronic renal failure
Time Frame: 3 months
Secondary Outcomes
- effects of a sympatholytic agent on cardiovascular reactivity to various stressors(3 months)